Ake Hjalmarson Gordon Tomaselli REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida N Engl J Med 2007;357 AKE HJAL
Ake Hjalmarson
Gordon Tomaselli
REFERENCE: Late Breaking Clinical Trials, Session 2, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
N Engl J Med 2007;357
AKE HJALMARSON, Sahlgrenska University, Göteborg
COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltimore
The lipid lowering agent rosuvastatin did not bring a significant benefit to older patients with systolic heart failure, according to the findings of the CORONA study released at the American Heart Association sessions in Orlando. Ake Hjalmarson talked with Peter Goodwin about the implications this has for using statins in older patients with heart failure.
[audio:https://www.audiomedica.com/podcasting/cardio/071105HjalmarsenTomaselliPODCAST.mp3]